Dr. Yarchoan is now speaking at #AACR23 with his presentation titled: “Malignancies in People with #HIV: Successes and Challenges at the Intersection of Virology, Immunology, and Oncology.” @NCIResearchCtr
LISTEN 🎧:Today is #AnalCancerAwarenessDay and this Healthcast podcast discusses a NCI-supported study which found that early treatment of precancerous lesions can cut #AnalCancer rates by more than half in people with #HIV. What does this mean for those at risk for anal cancer?
The pathophysiology of #KaposiSarcoma herpesvirus (KSHV)-associated multicentric #Castleman disease is driven by the expression of viral and human cytokines
https://t.co/fdOLKh4gny
#ICMH#HIVOnc updates: @MattPainschab presented important data demonstrating the safety and benefit of rituximab in HHV8-associated multicentric Castleman disease (MCD) in participants from Malawi. Discussions followed on how to identify MCD in limited resource settings.
Masterclass (as always) from @ramya_ramaswami on one of the most fascinating and complicated viruses around, KSHV!! Grateful to have her and HAMB team as colleagues, collaborators! @DrKateLurain
For anyone interested in HIV associated malignancy, cancer health disparities and virus associated cancers research - please join us at this virtual meeting later this month! Excited that our group’s research highlights will be presented @NCIResearchCtr #HIVOnc
To make a #COVID19 vaccine, researchers needed a lot of spike proteins ASAP. Dr. Dominic Esposito, director of the NCI Protein Expression Lab, tells us how his team produced the materials necessary to understand and fight COVID-19. https://t.co/B8xeUH2NLb #HispanicHeritageMonth
“While pathologic diagnosis is critical for KS diagnosis, unfortunately KS is most common in a part of the world there is a critical lack of pathologists and highly variable standards,” said Dr. Ethel Cesarman (@ecesarman) from @WCMCPathology#pathology
https://t.co/YoKU4kilMU
NEW: This Healthcast podcast looks at a NCI-supported study which found that early treatment of precancerous lesions can cut #AnalCancer rates by more than half in people with #HIV. What does this mean for those at risk for anal cancer? LISTEN 🎧: https://t.co/BkgKgVMot1
A cost-effectiveness analysis in Kenya reveals that paclitaxel is more cost-effective as a treatment for AIDS-associated Kaposi sarcoma than bleomycin-vincristine and increases life expectancy by 4.2 years https://t.co/ze2t0mKy2f
Thrilled to watch Dr. Li give awesome talk @kshv_workshop in Aurora. @NCIResearchCtr was well represented! I’ve really missed standing in line for coffee, science chitchats & even wearing badges. 👏 to @vanDykLab @linda_vandyk @ClambeyLab for organizing a terrific in-person mtg!
Perfect reminder that 1) @SztubaSolinska is awesome; 2) she's speaking at the satellite symposium @JessTucker202 and I are organizing and 3) I'm very excited for #ASV2022!
Meet Joanna Sztuba-Solinska @SztubaSolinska who studies #vRNA. Check out her #ASV2022 talk “Epitranscriptomic twist to the viral RNA structure-function relationship” at a Satellite Symposium: Controlling the Message: RNA Decay during Infection https://t.co/fIRoNB3zXC
ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents #AnalCancer in people with HIV. Guest editorial by @JPalefsky (@AMC_Studies) and Robert Yarchoan (@theNCI).
https://t.co/rRjD0KcsZV
NOW ENROLLING: Several clinical trials testing immunotherapy to treat #KaposiSarcoma are now accepting patients with or without #HIV or #AIDS. https://t.co/fJfYUzidPA @NCIResearchCtr